Validation of the Freiburg comorbidity index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 541-551

  Kleber, Martina ^a   Ihorst, Gabriele ^b   Groß, Barbara ^a   Koch, Bernd ^c   Reinhardt, Heike ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Center of Clinical Trials   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Comorbidity score; FCI; ISS; personalized treatment; Risk stratification

Indexed keywords

ADULT; AGED; CANCER PROGNOSIS; CANCER STAGING; CONFERENCE PAPER; FEMALE; FREIBURG COMORBIDITY INDEX; HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX; HUMAN; INTERNATIONAL STAGING SYSTEM; KAPLAN FEINSTEIN INDEX; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PREDICTION; STEM CELL; TRANSPLANTATION;

COMORBIDITY SCORE; FCI; ISS; PERSONALIZED TREATMENT; RISK STRATIFICATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84884137735     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.013     Document Type: Conference Paper

References (51)

1. S.V. Rajkumar, G. Gahrton, and P.L. Bergsagel Approach to the treatment of multiple myeloma: a clash of philosophies Blood 118 2011 3205 3211
2. M.Q. Lacy, J.B. Allred, and M.A. Gertz Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease Blood 118 2011 2970 2975
3. M. Cavo, S.V. Rajkumar, and A. Palumbo International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation Blood 117 2011 6063 6073
4. L.P. Fried, L. Ferrucci, and J. Darer Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care J Gerontol A Biol Sci Med Sci 59 2004 255 263
5. H. Ludwig, M. Beksac, and J. Blade Multiple myeloma treatment strategies with novel agents in 2011: a European perspective Oncologist 16 2011 388 403
6. S.Y. Kristinsson, O. Landgren, and P.W. Dickman Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 25 2007 1993 1999
7. A. Palumbo, S. Bringhen, and H. Ludwig Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) Blood 118 2011 4519 4529
8. S.J. Russell, and S.V. Rajkumar Multiple myeloma and the road to personalised medicine Lancet Oncol 12 2011 617 619
9. M. Kleber, G. Ihorst, and M. Terhorst Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score Blood Cancer J 1 2011 e35
10. S.K. Kumar, J.R. Mikhael, and F.K. Buadi Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines Mayo Clin Proc 84 2009 1095 1110
11. M.L. Sorror, B.M. Sandmaier, and B.E. Storer Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 2007 4246 4254
12. M.L. Sorror, M.B. Maris, and R. Storb Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2005 2912 2919
13. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
14. M.H. Kaplan, and A.R. Feinstein The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus J Chronic Dis 27 1974 387 404
15. L. Labonte, T. Iqbal, and M.A. Zaidi Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma Biol Blood Marrow Transplant 14 2008 1039 1044
16. M. Kleber, G. Ihorst, and B. Deschler Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients Eur J Haematol 83 2009 519 527
17. A. Markert, V. Thierry, and M. Kleber Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment Int J Cancer 124 2009 722 728
18. M. Engelhardt, G. Ihorst, and J. Udi Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness? a systemic approach by detailed analysis via the Electronic Tumor Base Documentation System Onkologie 34 2011 688 694
19. M. Kleber, M. Cybulla, and K. Bauchmuller Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice Ann Oncol 18 2007 950 958
20. K. Matsushita, B.K. Mahmoodi, and M. Woodward Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate JAMA 307 2012 1941 1951
21. R.A. Knudson, B.M. Shearer, and R.P. Ketterling Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia Cancer Genet Cytogenet 175 2007 8 18
22. D. Berger, R. Engelhardt, and R. Mertelsmann The red book 4th edition 2010 Ecomed Landsberg/Lech, Germany
23. M. Engelhardt, D. Berger, and R. Mertelsmann The blue book 3rd edition 2010 Springer Heidelberg, Germany
24. M. Engelhardt, J. Udi, and M. Kleber European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma Leuk Lymphoma 51 2010 2006 2011
25. M. Engelhardt, M. Kleber, and J. Udi Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches Leuk Lymphoma 51 2009 1424 1443
26. K. Neben, H.M. Lokhorst, and A. Jauch Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Blood 119 2012 940 948
27. G.J. Morgan, F.E. Davies, and W.M. Gregory Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results Haematologica 97 2012 442 450
28. A. Palumbo, F. Cavallo, and I. Hardan Melphalan/prednisone/lenalidomide (MPR) versus high- dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65 years: results of a randomized phase III study Blood 118 2011 abstract 3069
29. B.M. Augustson, G. Begum, and J.A. Dunn Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party J Clin Oncol 23 2005 9219 9226
30. S.V. Rajkumar Treatment of multiple myeloma Nat Rev Clin Oncol 8 2011 479 491
31. B. Deschler, G. Ihorst, and U. Platzbecker Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome Haematologica 98 2013 208 216
32. V. Eleutherakis-Papaiakovou, A. Bamias, and D. Gika Renal failure in multiple myeloma: incidence, correlations, and prognostic significance Leuk Lymphoma 48 2007 337 341
33. J.W. Chien, and K.M. Sullivan Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 15 2009 447 453
34. L. Farina, B. Bruno, and F. Patriarca The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non- myeloablative allogeneic stem cell transplantation Leukemia 23 2009 1131 1138
35. M.A. Dimopoulos, E. Kastritis, and E. Katodritou The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation has an independent prognostic value for overall survival in newly-diagnosed patients with symptomatic multiple myeloma: comparison with 3 other equations for GFR estimation Blood 120 2012 abstract 1849
36. J.L. Carter, P.E. Stevens, and J.E. Irving Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age QJM 104 2011 839 847
37. P.R. Greipp, J. San Miguel, and B.G. Durie International staging system for multiple myeloma J Clin Oncol 23 2005 3412 3420
38. C. Jakob, J. Sterz, and P. Liebisch Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma Leukemia 22 2008 1767 1772
39. K. Neben, A. Jauch, and U. Bertsch Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation Haematologica 95 2010 1150 1157
40. P. Kapoor, and S.V. Rajkumar Update on risk stratification and treatment of newly diagnosed multiple myeloma Int J Hematol 94 2011 310 320
41. H. Avet-Loiseau, M. Attal, and L. Campion Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival J Clin Oncol 30 2012 1949 1952
42. S. Firat, M. Bousamra, and E. Gore Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 52 2002 1047 1057
43. L. Repetto, L. Fratino, and R.A. Audisio Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study J Clin Oncol 20 2002 494 502
44. R. Simon, and D.G. Altman Statistical aspects of prognostic factor studies in oncology Br J Cancer 69 1994 979 985
45. P. Armand, C.J. Gibson, and C. Cutler A disease risk index for patients undergoing allogeneic stem cell transplantation Blood 120 2012 905 913
46. M. Breccia, A.M. Frustaci, and L. Cannella Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients Hematol Oncol 27 2009 148 153
47. P. Chevallier, M. Labopin, and P. Turlure A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study Leukemia 25 2011 939 944
48. M. Offidani, C. Polloni, and L. Corvatta Assessment of frailty measures and their effect on survival in a population of patients registered at Marche region Multiple Myeloma (MM) Registry Blood 118 2011 abstract 2873
49. H. Ludwig, B.G. Durie, and V. Bolejack Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group Blood 111 2008 4039 4047
50. A. Savic, V. Kvrgic, and N. Rajic The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients Leuk Res 36 2012 479 482
51. J. Horn, M. Kleber, and S. Hieke Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance Ann Hematol 91 2012 1579 1586